Blauvelt, A <br/><br/>
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.  [electronic resource] 

 -  The British journal of dermatology  09 2018 
 - 615-622 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/bjd.16724  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Candida albicans--immunology<br/>Candidiasis--epidemiology<br/>Cardiovascular Diseases--chemically induced<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>Dose-Response Relationship, Drug<br/>Etanercept--administration & dosage<br/>Female<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Inflammatory Bowel Diseases--epidemiology<br/>Interleukin-23 Subunit p19--antagonists & inhibitors<br/>Male<br/>Middle Aged<br/>Placebos--administration & dosage<br/>Psoriasis--diagnosis<br/>Randomized Controlled Trials as Topic<br/>Severity of Illness Index<br/>Time Factors<br/>Treatment Outcome